Skip To Main Content
Arthur Allen on Muck Rack

Arthur Allen

Verified
Washington, D.C.
As seen in: KFF Health News, CNN, MSN, MSN Australia, MSN India, MSN UK, The Washington Post, USA Today, Yahoo Canada, Yahoo News, Yahoo News Malaysia and
Senior Correspondent @kffhealthnews, formerly @Politico. Author, The Fantastic Laboratory of Dr. Weigl, Ripe, and Vaccine. arthura@kff.org
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Arthur

Contact Arthur, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

How Much Of A Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages

|
By Arthur Allen Verified
| Drugs.com
By Arthur Allen and KFF Health News HealthDay Reporters Medically reviewed by Drugs.com via HealthDay MONDAY, Aug. 24, 2026 — Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill. For six months in 2022, Manski received monthly infusions of nivolumab to fight advanced melanoma.
Open in Who Shared Issue with article?

Customize your cookie preferences

|
By Arthur Allen Verified, Arthur Allen
| HealthDay Verified
MONDAY, Aug. 24, 2026 (HealthDay News) — Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill. For six months in 2022, Manski received monthly infusions of nivolumab to fight advanced melanoma.
Open in Who Shared View Duplicates (4) Issue with article?

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

|
By Arthur Allen Verified
| Philly Voice Verified
Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill. For six months in 2022, Manski received monthly infusions of nivolumab to fight advanced melanoma. The drug ruined his thyroid gland, he said, requiring him to go on a special medication for the rest of his life, and caused severe dryness in his eyes, lips, and mouth.
Open in Who Shared Issue with article?
See all 4,053 licensed articles (4,346 Total)